Needs a couple good catalysts. Unfortunate but many bio have poor price action until really good news bumps it to a new level. My timeframe is q1 or q2 2019.
But hopefully phase 2 injunctive starts and patent in US issued for 2017 catalysts. Q1 2018 should produce NIH results.
Not that it means much right now, but this little stock is on many big pharma watch list.
Risk reward here is low price and a possible blockbuster drug. Similar intravenous drug was bought for the equivalent with milestones of over 75 a share.
News 
Market Data 
Discover 
